Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

@inproceedings{UreaTorres2014ChangesIF,
  title={Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial},
  author={Pablo Antonio Ure{\~n}a-Torres and Dominique Pri{\'e} and Karim Keddad and P. Preston and P. A. W. J. de Wilde and Hong I. Wan and John Brian Copley},
  booktitle={BMC nephrology},
  year={2014}
}
BACKGROUND High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate absorption using lanthanum carbonate on FGF23 levels in normophosphatemic patients with CKD stage 3. METHODS Thirty-five individuals were randomized to lanthanum carbonate 3000 mg/day (n=23) or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
13 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Acute effects of very-low-protein diet on FGF23 levels: a randomized study

  • B Di Iorio, L Di Micco, +5 authors D Russo
  • Clin J Am Soc Nephrol
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…